SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine AB (OMX Nordic Exchange: AERO) today announces the signing of an exclusive agreement with UK & Irish medical device company Healthcare 21 Ltd for sales, marketing and distribution of Aerocrine’s new airway inflammation monitor and test kit – NIOX VERO® – across the UK and Ireland.
The agreement goes into effect on February 1, 2014 and gives Healthcare 21 exclusive rights for the sales marketing and distribution of Aerocrine’s new instrument NIOX VERO® and test kits, used for diagnosing and monitoring patients with asthma. The agreement also includes Healthcare 21 taking on the support, sales and distribution for the already installed base of Aerocrine’s NIOX MINO® devices across the UK & Irish market. “As we continue the roll out of our new product, NIOX VERO® in the UK and Ireland, we are delighted to be partnering with Healthcare 21, who is a leading sales and marketing distributor with an existing and substantial UK & Irish operation and proven track record of success in the respiratory and secondary care market. This deal is part of Aerocrine’s strategy of substantially growing the European business in a cost-efficient manner,” says David Plotts, Aerocrine VP of International Sales & UK General Manager.
Aerocrine is committed to maintaining a substantial profile and direct presence in the UK and Irish market to support development of FeNO guidelines, KOL management, engagement with payers with particular focus and attention on the primary care sector. Aerocrine will also directly continue to focus on developing opportunities as a result of forthcoming NICE Guidance on FeNO and in new healthcare environments such as pharmacy and occupational health. Aerocrine offers versatile and easy-to-use monitoring devices for fractional exhaled Nitric Oxide (FeNO)-testing. Aerocrine’s compact hand-held devices for research and clinical applications are used for routine measurements in both specialist and primary care clinics, and can be used to improve the management of allergic airway inflammation, such as asthma.
“We are delighted to partner with Aerocrine in the UK and Ireland and we look forward to supporting both existing and future customers whilst also working with Aerocrine to establish FeNO testing as the standard of care method for measuring allergic airway inflammation in our marketplaces” says David Frederick, MD of Healthcare21 NIOX VERO® and NIOX MINO® offer added advantages for patient care, including detecting allergic airway inflammation, determining the likelihood of corticosteroid responsiveness, monitoring of airway inflammation to determine the potential need for corticosteroid, and unmasking of otherwise unsuspected non-adherence to corticosteroid therapy.
About Healthcare 21
The Healthcare 21 Group is a leading privately owned medtech sales and marketing group of companies with an existing and substantial infrastructure in the UK & Ireland. HC21 works in diversified fields and has long term distribution agreements with leading multinational organizations.
Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.
Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on January 17, 2014.
This information was brought to you by Cision http://news.cision.com